Our executive team will be participating in several upcoming investor and industry conferences. Come see us! https://bit.ly/3Xn5859 Stephane van Rooijen Andrew Denker Mark Gidjunis #clinicaloncology
About us
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.
- Website
-
www.flamingotx.com
External link for Flamingo Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at Flamingo Therapeutics
Updates
-
ICYMI: First Patients Dosed in the United Kingdom and Korea in ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC), joining sites already open in the United States. https://bit.ly/3YUP2RJ #clinicaloncology #headandneck
-
-
First Patients Dosed in the United Kingdom and Korea in ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC), joining sites already open in the United States. https://bit.ly/3YUP2RJ #clinicaloncology #headandneck
-
-
First Patients Dosed in the United Kingdom and Korea in ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC), joining sites already open in the United States. https://bit.ly/3YUP2RJ #clinicaloncology #headandneck
-
-
Flamingo Therapeutics reposted this
World Head and Neck Cancer Day! ✨🌍 Join us in raising awareness and supporting individuals affected by oral, head, and neck cancers. SPOHNC offers essential resources and publications tailored to meet the needs of patients and survivors. 💪💙 #WorldHeadAndNeckCancerDay #oralcancer #headandneckcancer #cancerawareness #support #community #survivors #patients #togetherweheal
-
-
Today is World Head and Neck Cancer Awareness Day. Join our flock in raising awareness of the symptoms of cancers of the head and neck. If you or someone you know is experiencing any of these symptoms, consult a doctor. #headandneckcancer
-
-
Flamingo Therapeutics reposted this
As July 27th approaches, let's come together for World Head and Neck Cancer Day! 🌟🌍 Join us in spreading awareness and supporting those affected by oral, head, and neck cancers. Together, we can make a difference! #WorldHeadAndNeckCancerDay #RaiseAwareness #oralcancer #headandneckcancer #patients #survivors #support #community #bettertogether #youarenotalone #togetherweheal
-
-
Flamingo CEO Stephane van Rooijen will be part of the Euronext Life Science Leaders’ conference and participate in the panel discussion "Exit Opportunities and Fundraising in More Challenging Times." Reach out to connect! Sophie Stegen Jacob Mekhael
-
-
Flamingo’s Marie-Aline Neveu is at the Annual Congress of the European Association for Cancer Research (EACR) where she presented her poster: “Preclinical development of FTX-001: First-in-class inhibitor of the long non-coding RNA MALAT1." Read more: https://bit.ly/45hYGyM
-
-
Flamingo presents poster at EACR 2024 Congress on FLM-7523 (FTX-001), a first-in-class inhibitor of the long non-coding RNA MALAT1. Read more: https://bit.ly/45hYGyM #EACR2024
-